Professor Gary Maartens is both head of clinical pharmacology at the University of Cape Town (UCT) and a chief specialist physician at Groote Schuur Hospital. Earlier this year, South Africa’s National Research Foundation (NRF) recognised his contribution to the field by awarding him an A rating.
A breakthrough study conducted by Professor Keertan Dheda and Dr Michele Tomasicchio, at the University of Cape Town’s (UCT) Centre for Lung Infection and Immunity, has revealed that one of South Africa’s most commonly-used injectable contraceptives could potentially increase women’s chances of contracting tuberculosis (TB).
In 2015, Dr Nadia Ikumi (née Chanzu) - a young Kenyan scientisty - became the first African to be awarded a postdoctoral fellowship by the AXA Research Fund. A researchers at the Institure of Infectious Disease and Molecular Medicine at the University of Cape Town (UCT), Ikumi aims to understand the influence of the HIV infection on the immune system of pregnant women and their unborn children.
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town's (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduations ceremony on Saturday, 13 April.
Seven young University of Cape Town (UCT) scholars are among the inaugural 2019 cohort of Future Leaders – African Independent Research (FLAIR) Fellows. FLAIR Fellowships are awarded to talented African early-career researchers who have the potential to become leaders in their fields.
The University of Cape Town’s (UCT) Institute of Infectious Disease and Molecular Medicine (IDM) is based within the Faculty of Health Sciences (FHS). The Institute is a leading research centre on infectious disease in Africa. Speaking to the IDM’s positionality, Director, Professor Valerie Mizrahi says: “Unfortunately, we have a high burden of TB in this country and Cape Town is a heavily TB-burdened city, with high rates of HIV co-infection. However, we have a strong group of TB researchers in the IDM and elsewhere in the University. Our research groups have established outstanding clinical and laboratory capabilities for investigating new ways to intervene in TB by working at the intersection of the laboratory, clinic, and community. We are able to bring many disciplines to bear on this problem.”
Professor Ed Rybicki, the Director of the Biopharming Research Unit of the University of Cape Town’s (UCT’s) Molecular and Cell Biology Department, and member of the Institute of Infectious Disease and Molecular Medicine (IDM) has received an award which he says, acknowledges their long history in creating intellectual property (IP) at UCT.
The University of Cape Town (UCT’s) Institute of Infectious Disease and Molecular Medicine (IDM), based in the Faculty of Health Sciences (FHS) is one of the world’s leading research centres on infectious disease. To commemorate World TB Day, the IDM hosted their 2nd Annual World Tuberculosis Day NanoSymposium to showcase research conducted by leading scientists and researchers in the field. The programme included a line-up of UCT researchers as well as keynote speaker Professor Bryan Bryson from MIT/Harvard.
The international PravaTB consortium has recently received a prestigious 4.9 million Euro award from the European & Developing Countries Clinical Trials Partnership (EDCTP) to conduct a clinical trial investigating the use of statins to prevent chronic lung inflammation and potentially TB relapse.
What roles do talking and breathing play in the spread of tuberculosis (TB)? How quickly does treatment prevent transmission of the infection? A University of Cape Town (UCT) research team has been awarded funding to answer these questions and in turn benefit the communities most affected by the disease.